Stifel Maintains Buy on 10x Genomics, Lowers Price Target to $53
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Daniel Arias maintains a Buy rating on 10x Genomics (TXG) but lowers the price target from $63 to $53.

May 01, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Stifel maintains a Buy rating on 10x Genomics but lowers the price target from $63 to $53.
While the reduction in price target could suggest a tempered outlook on the stock's short-term price potential, the maintenance of a Buy rating indicates a continued positive view on the company's fundamentals and long-term prospects. This mixed signal could lead to neutral short-term price movement as investors weigh the lowered price target against the reaffirmed confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100